To include your compound in the COVID-19 Resource Center, submit it here.

Symlin pramlintide: AMLN plans to run a double-blind, placebo-controlled dose titration study in 250 patients with Type I diabetes who are actively trying to im

The dose titration study, which is expected to start this quarter, will evaluate safety, HbA1c levels and insulin usage. Patients will

Read the full 219 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE